Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis

International Journal of Dermatology

Volumn 37, Issue 2, 1998, Pages 142-144

  Maloney, J ^a,d   Morman, Manuel R ^b   Stewart, Daniel M ^c   Tharp, Michael D ^b   Brown, Jeanine Johnson ^b   Rajagopalan, Rukmini ^a  

^a Cherry Creek Dermatology   (United States)

^b Midwest Cutaneous Research Corp   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; EMOLLIENT AGENT;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

EID: 0031925616     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1998.00394.x     Document Type: Article

References (2)

1. Marks R. Adverse side effects from the use of topical corticosteroids. In: Maibach HI, Surber C, eds. Topical Corticosteroids. Basel, Switzerland: S. Karger, 1991: 170-183.
2. Data on file, Glaxo Dermatology, Glaxo Wellcome Inc., Research Triangle Park, North Carolina.